Cargando…
First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort
BACKGROUND/AIMS: Aim of this retrospective study was to analyze the efficacy, safety, and predictors of treatment success for first-generation-PI triple therapies, including either boceprevir or telaprevir, in a mono-centric “real-life” setting with respect to SVR 24. PATIENTS: 131 patients (102 pat...
Autores principales: | Werner, Christoph R, Franz, Carolin, Egetemeyr, Daniel P, Beck, Robert, Malek, Nisar P, Lauer, Ulrich M, Berg, Christoph P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355422/ https://www.ncbi.nlm.nih.gov/pubmed/25889921 http://dx.doi.org/10.1186/s12985-015-0261-0 |
Ejemplares similares
-
Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013) -
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
por: Werner, Christoph R, et al.
Publicado: (2016) -
Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021) -
SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
por: Thorlund, Kristian, et al.
Publicado: (2014) -
SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study
por: Sheikh, Naukhaiz Taqi, et al.
Publicado: (2022)